<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28492789</article-id><article-id pub-id-type="pmc">5409253</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2016-0025</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Single-Dose Lignocaine-Based Blood Cardioplegia in Single Valve
Replacement Patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ramani</surname><given-names>Jaydip</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/></contrib><contrib contrib-type="author"><name><surname>Malhotra</surname><given-names>Amber</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Wadhwa</surname><given-names>Vivek</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sharma</surname><given-names>Pranav</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Garg</surname><given-names>Pankaj</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tarsaria</surname><given-names>Malkesh</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Pandya</surname><given-names>Himani</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff2">2</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Cardiovascular and Thoracic Surgery of U.N. Mehta
Institute of Cardiology and Research Center (Affiliated to B.J. Medical College),
Civil hospital Campus, Asarwa, Ahmedabad, India.</aff><aff id="aff2"><label>2</label>Department of Cardiovascular and Thoracic Surgery of U.N. Mehta
Institute of Cardiology and Research Center (Affiliated to B.J. Medical College),
Civil hospital Campus, Asarwa, Ahmedabad, India.</aff><author-notes><corresp id="c1">Correspondence Address: Jaydip Ramani, U.N. Mehta Institute of
Cardiology and Research Center (Affiliated to B. J. Medical College), New Civil
Hospital Campus, Department of Cardiovascular and Thoracic Surgery, Asarwa,
Ahmedabad-380016, Gujarat, India. E-mail:
<email>jaydipdhara154@gmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Mar-Apr</season><year>2017</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Mar-Apr</season><year>2017</year></pub-date><volume>32</volume><issue>2</issue><fpage>90</fpage><lpage>95</lpage><history><date date-type="received"><day>23</day><month>9</month><year>2016</year></date><date date-type="accepted"><day>24</day><month>11</month><year>2016</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p> Myocardial protection is the most important in cardiac surgery. We compared
our modified single-dose long-acting lignocaine-based blood cardioplegia
with short-acting St Thomas 1 blood cardioplegia in patients undergoing
single valve replacement.</p></sec><sec><title>Methods</title><p>A total of 110 patients who underwent single (aortic or mitral) valve
replacement surgery were enrolled. Patients were divided in two groups based
on the cardioplegia solution used. In group 1 (56 patients), long-acting
lignocaine based-blood cardioplegia solution was administered as a single
dose while in group 2 (54 patients), standard St Thomas IB (short-acting
blood-based cardioplegia solution) was administered and repeated every 20
minutes. All the patients were compared for preoperative baseline
parameters, intraoperative and all the postoperative parameters.</p></sec><sec><title>Results</title><p>We did not find any statistically significant difference in preoperative
baseline parameters. Cardiopulmonary bypass time were 73.8&#x000b1;16.5 and
76.4&#x000b1;16.9 minutes (<italic>P</italic>=0.43) and cross clamp time were
58.9&#x000b1;10.3 and 66.3&#x000b1;11.2 minutes (<italic>P</italic>=0.23) in
group 1 and group 2, respectively. Mean of maximum inotrope score was
6.3&#x000b1;2.52 and 6.1&#x000b1;2.13 (<italic>P</italic>=0.65) in group 1 and
group 2, respectively. We also did not find any statistically significant
difference in creatine-phosphokinase-MB (CPK-MB), Troponin-I levels, lactate
level and cardiac functions postoperatively.</p></sec><sec><title>Conclusion</title><p> This study proves the safety and efficacy of long-acting lignocaine-based
single-dose blood cardioplegia compared to the standard short-acting
multi-dose blood cardioplegia in patients requiring the single valve
replacement. Further studies need to be undertaken to establish this
non-inferiority in situations of complex cardiac procedures especially in
compromised patients.</p></sec></abstract><kwd-group><kwd>Cardiopulmonary Bypass</kwd><kwd>Cardioplegic Solutions</kwd><kwd>Lidocaine</kwd><kwd>Heart Valves/Surgery</kwd><kwd>Aortic Valve/Surgery</kwd><kwd>Mitral Valve/sSurgery</kwd></kwd-group></article-meta></front><body><table-wrap id="t5" orientation="portrait" position="anchor"><table frame="hsides" rules="groups" style="background-color:#e6e7e8"><colgroup span="1"><col width="20%" span="1"/><col width="80%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Abbreviations, acronyms &#x00026; symbols</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">AF</td><td align="left" rowspan="1" colspan="1">= Atrial fibrillation</td></tr><tr><td align="left" rowspan="1" colspan="1">CMIA</td><td align="left" rowspan="1" colspan="1">= Chemiluminescent microparticle immunoassay</td></tr><tr><td align="left" rowspan="1" colspan="1">CPB</td><td align="left" rowspan="1" colspan="1">= Cardiopulmonary bypass</td></tr><tr><td align="left" rowspan="1" colspan="1">CPK-MB</td><td align="left" rowspan="1" colspan="1">= Creatine-phosphokinase-MB</td></tr><tr><td align="left" rowspan="1" colspan="1">ICU</td><td align="left" rowspan="1" colspan="1">= Intensive care unit</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Myocardial protection in its largest definition includes all drugs and techniques
used to maintain or to protect the cellular integrity of the myocardial cell against
the devastating effect of oxygen deprivation. The main principles of myocardial
protection are reduction of metabolic activity by hypothermia and therapeutic arrest
of the electrical activity and contractile apparatus of the myocytes by
administering cardioplegic solution (<italic>e.g.</italic>, depolarization of the
membrane potential by high potassium blood cardioplegia<sup>[<xref rid="r1" ref-type="bibr">1</xref>-<xref rid="r3" ref-type="bibr">3</xref>]</sup>.</p><p>Myocardial protection against global ischemia-reperfusion injury during open-heart
surgery with cardiopulmonary bypass (CPB) and cardioplegic arrest remains a
challenging problem. A recent survey of UK practice found that 56% of surgeons use
cold blood cardioplegia, 14% use warm blood cardioplegia, 14% use crystalloid
cardioplegia, 21% use retrograde infusion and 16% do not use any
cardioplegia<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>.</p><p>Short-acting blood cardioplegia requires repetition at every 20 minutes with
interruption of ongoing surgical procedure. Crystalloid cardioplegia is repeated at
every 60 minutes but it causes significant hemodilution. Therefore, to come over
these problems, we modified our blood cardioplegia which has advantage of both blood
and crystalloid cardioplegia.</p><p>We modified our routine standard blood cardioplegia with additives over period of
time and we have been using this modified cardioplegia as a single-dose long-acting
blood cardioplegia over many years. In this study, efficacy of modified long-acting
lignocaine-based blood cardioplegia solution on myocardial protection was compared
with the short-acting St Thomas I blood-based cardioplegia in patients undergoing
single valve (mitral or aortic) replacement surgery.</p></sec><sec sec-type="methods"><title>METHODS</title><sec><title>Study Population and Design</title><p>We conducted a prospective randomized controlled study of 110 patients who
underwent single (aortic or mitral) valve replacement surgery between June 2013
and August 2015 in Department of Cardiovascular and Thoracic Surgery at U.N.
Mehta Institute of Cardiology and Research Center , Ahmedabad, India, after
taking consent of all patients and ethical committee approval. Patients were
divided in two groups based on the cardioplegia solution used. In group 1 (56
patients), long-acting lignocaine-based blood cardioplegia solution was
administered as a single dose while in group 2 (54 patients), standard St Thomas
I B (short-acting blood-based cardioplegia solution) was administered and
repeated every 20 minutes. We excluded two patients from group 2 who required
modified Bentall's procedure. In all patients, cardioplegia was delivered by
antegrade method with topical surface cooling of heart. We included the patients
undergoing single valve (mitral or aortic) replacement surgery with or without
tricuspid valve repair. Patients with severe left ventricular dysfunction
(ejection fraction &#x0003c; 35%), double valve replacement, valve repair
(mitral/aortic), emergency surgery, New York Heart Association class IV,
associated coronary artery disease, and redo surgery were excluded from the
study. Apart from preoperative baseline parameters, patients were compared for
intraoperative parameters like coronary sinus blood sample analysis at 20, 40,
60 minutes, aortic cross clamp time, CPB time, rhythm disturbances and need for
pacing. Patients were also compared for postoperative parameters like serum
creatine-phosphokinase-MB (CPK-MB) and lactate at 6, 12, 24 and 48 hours,
cardiac output at 24, 48 and 72 hours, arrhythmias, inotropic score, blood
investigations on 1<sup>st</sup>, 3<sup>rd</sup> and 7<sup>th</sup> day, 2D
echocardiography on 5<sup>th</sup> day, intensive care unit (ICU) stay, hospital
stay and postoperative complications.</p></sec><sec><title>Anesthetic and Surgical Protocol</title><p>Anesthesia was induced with midazolam 0.1 mg/kg, fentanyl 5 &#x000b5;g/kg and
vecuronium 0.1 mg/kg, glycopyrollate 40 &#x000b5;g/kg stat and maintained with
sevofluorane, vecuronium, oxygen, and air and injection fentanyl during single
valve replacement. Following induction, a Swan-Ganz thermistor-tipped catheter
was inserted via internal jugular vein and remained <italic>in situ</italic> for
72 hours. All baseline values and hemodynamic data were recorded. Inotropes were
prepared as per-protocol and postoperative inotropic score was calculated.</p><p>All operations were performed through midline sternotomy using CPB with
extracorporeal circulation using aorto-bicaval cannulation and moderate
hypothermia. Retrograde coronary sinus cannulation was done in all patients.
Antegrade aortic root (or coronary ostial cardioplegia during aortic valve
replacement) was delivered. Coronary sinus blood samples were collected from one
port of retrograde cannula. In case of single-dose blood cardioplegia group,
samples were also collected at every 20 minutes after flushing with small amount
of cardioplegia solution.</p></sec><sec><title>Myocardial Protection</title><sec><title>Method of Preparation of Cardioplegia</title><list list-type="roman-upper"><list-item><p>Single-dose long-acting blood cardioplegia: As mentioned in <xref ref-type="table" rid="t1">Table 1</xref>, constituents added in
200 ml Ringer lactate are 13 ml of sodium bicarbonate, 5 ml of
potassium chloride, 16 ml of 20% mannitol, 4 ml of 50% magnesium
sulphate, 7 ml of 2% lignocaine, 2 ml of dexamethasone, and then 800
ml blood added to it, thus making it a solution of 4:1 blood and
crystalloid similar to St Thomas I B cardioplegia.</p><p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Cardioplegia composition.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="33%" span="1"/><col width="33%" span="1"/><col width="33%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Components</th><th align="center" rowspan="1" colspan="1">Group 1</th><th align="center" rowspan="1" colspan="1">Group 2</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Base solution</td><td align="center" rowspan="1" colspan="1">200 ml Ringer lactate</td><td align="center" rowspan="1" colspan="1">200 ml normal saline</td></tr><tr><td align="left" rowspan="1" colspan="1">Sodium</td><td align="center" rowspan="1" colspan="1">140</td><td align="center" rowspan="1" colspan="1">142</td></tr><tr><td align="left" rowspan="1" colspan="1">Potassium</td><td align="center" rowspan="1" colspan="1">13 mEq</td><td align="center" rowspan="1" colspan="1">16 mEq</td></tr><tr><td align="left" rowspan="1" colspan="1">Sodium bicarbonate</td><td align="center" rowspan="1" colspan="1">24 mEq</td><td align="center" rowspan="1" colspan="1">24 mEq</td></tr><tr><td align="left" rowspan="1" colspan="1">Magnesium</td><td align="center" rowspan="1" colspan="1">24 mEq</td><td align="center" rowspan="1" colspan="1">16 mEq</td></tr><tr><td align="left" rowspan="1" colspan="1">Calcium</td><td align="center" rowspan="1" colspan="1">1 mmol/l</td><td align="center" rowspan="1" colspan="1">1.7 mmol/l</td></tr><tr><td align="left" rowspan="1" colspan="1">Osmolality</td><td align="center" rowspan="1" colspan="1">320 mOsm/l</td><td align="center" rowspan="1" colspan="1">310 mOsm/l</td></tr><tr><td align="left" rowspan="1" colspan="1">Steroid</td><td align="center" rowspan="1" colspan="1">Dexamethasone 16 mg</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">Lignocaine/procaine</td><td align="center" rowspan="1" colspan="1">130 mg 2% lignocaine</td><td align="center" rowspan="1" colspan="1">13.64 mg 1% procaine</td></tr><tr><td align="left" rowspan="1" colspan="1">20% mannitol</td><td align="center" rowspan="1" colspan="1">16 ml mannitol</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">Blood</td><td align="center" rowspan="1" colspan="1">800 ml of cold blood</td><td align="center" rowspan="1" colspan="1">800 ml of cold blood</td></tr><tr><td align="left" rowspan="1" colspan="1">Final composition</td><td align="center" rowspan="1" colspan="1">4 part blood:1 part
cardioplegia</td><td align="center" rowspan="1" colspan="1">4 part blood:1 part
cardioplegia</td></tr></tbody></table></table-wrap></p></list-item><list-item><p>Short-acting St Thomas I B cardioplegia: As mentioned in <xref ref-type="table" rid="t1">Table 1</xref>, constituents are added
in 200 ml normal saline and then 800 ml blood added to it, thus
making it a solution of 4:1 blood and crystalloid.</p><list list-type="bullet"><list-item><p>Group 1 - Single-dose lignocaine-based blood cardioplegia
solution: Cardioplegia was given in dose of 30 ml/kg over
5-8 minutes with pressure of 80-100 mmHg and temperature of
20&#x000ba; C as single-dose cardioplegia.</p></list-item><list-item><p>Group 2 - Short-acting St Thomas I B cardioplegia:
Cardioplegia was given in dose of 30 ml/kg over 5-8 minutes
with pressure of 80-100 mmHg and temperature of 20&#x000ba; C and
repeated every 20 minutes.</p></list-item></list></list-item></list></sec></sec><sec><title>Arrhythmias</title><p>Patients were compared for rhythm changes intraoperatively and postoperatively
(up to 7<sup>th</sup> day). New-onset postoperative atrial fibrillation (AF) was
defined (STS Adult Cardiac Surgery Database) as AF occurring during
hospitalization after cardiac surgery in a patient with no history of AF or if
AF lasts for more than 10 minutes that requires medical treatment. Other
arrhythmias including ventricular tachycardia (lasting for more than 30
seconds), ventricular fibrillation, hemodynamically significant premature
contractions (more than grade 3 - multiform, repetitive, R on T pattern
according to Lown grading) and post-operative heart block were also noted.</p></sec><sec><title>Cardiac Biomarkers</title><p>CPK-MB enzymatic basal level was measured which was 20-25 U/l. It is measured by
IFCC method/immunoinhibition performed on architect system (Abbott Laboratory).
The upper normal reference limit (99<sup>th</sup> percentile) was less than 24
U/l. Blood CPK-MB of &#x0003e; 125 U/l (five times the basal value) was considered to
be significant. Serum cardiac troponin-I concentration was measured by
chemiluminescent microparticle immunoassay (CMIA) on architect system (Abbott
Laboratory). The upper normal reference limit (99<sup>th</sup> percentile) was
less than 0.03 ng/mL. Blood lactate of &#x0003e; 4 ng/dl was taken as significant
value.</p></sec><sec><title>Perioperative Myocardial Infarction</title><p>Two of the following 3 criteria had to be fulfilled to diagnose a perioperative
myocardial infarction: 1) CK-MB and/or troponin-T elevation above normal limits.
2) Appearance of a new postoperative Q wave on the electrocardiogram of more
than 0.03 second. 3) A new hypokinetic or akinetic area in the left or right
ventricle by 2D echocardiography.</p></sec><sec><title>Statistical Analysis</title><p>Statistical data were analyzed using SPSS version 22 software system. Continuous
data were expressed as mean&#x000b1;SD. Univariate analysis of continuous data
was performed using Chi-square test or through a Student's t-test. Level of
significance was accepted at <italic>P</italic>&#x0003c;0.05.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>All preoperative baseline parameters were comparable (<xref ref-type="table" rid="t1">Table 1</xref>). There was no significant difference in the frequency of
mechanical ventilation time 6.83&#x000b1;2.33 and 6.34&#x000b1;2.10
(<italic>P</italic>=0.63) minutes, hospital stay 8.63&#x000b1;3.20 and
8.08&#x000b1;2.52 (<italic>P</italic>=0.72) days, myocardial infarction, inotropic
support score 6.3&#x000b1;2.52 and 6.1&#x000b1;2.13 (<italic>P</italic>=0.65), and/or
30-day mortality between the two groups. In this study, mean aortic cross clamp time
in single-dose blood cardioplegia Group 1 was 58.9&#x000b1;10.3 min
<italic>vs.</italic> 66.3&#x000b1;11.2 min (<italic>P</italic>=0.23) for ST 1 B
Group 2. Mean CPB time in single-dose blood cardioplegia group was 73.8&#x000b1;16.5
min <italic>vs.</italic> 76.4&#x000b1;16.9 min (<italic>P</italic>=0.43) in ST 1 B
Group 2. The cross clamp time was slightly shorter in the single-dose blood
cardioplegia group owing to the repetitions required in the ST 1 B Group 2 as shown
in <xref ref-type="table" rid="t2">Table 2</xref>. We did not find any statistical
significant difference in aortic cross clamp and CPB time and its effect on
intraoperative and postoperative recovery of cardiac rhythm and function. In
coronary sinus blood samples pH, pCO<sub>2</sub>, pO<sub>2</sub>, sodium, potassium,
glucose, hematocrit, calcium, lactate levels in both groups were comparable. No
statistically significant differences were found between the two groups. We also did
not find any statistical significant difference in postoperative serum CPK-MB,
troponin I and lactate at 6, 12, 24 and 48 hours, cardiac output study at 24, 48 and
72 hours. All parameters were comparable (<xref ref-type="table" rid="t3">Tables
3</xref> and <xref ref-type="table" rid="t4">4</xref>).</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Patient characteristics.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Characteristics</th><th align="center" rowspan="1" colspan="1">Group 1</th><th align="center" rowspan="1" colspan="1">Group 2</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">37&#x000b1;12</td><td align="center" rowspan="1" colspan="1">32&#x000b1;14</td><td align="center" rowspan="1" colspan="1">0.41</td></tr><tr><td align="left" rowspan="1" colspan="1">Females (%)</td><td align="center" rowspan="1" colspan="1">28 (50%)</td><td align="center" rowspan="1" colspan="1">36 (65%)</td><td align="center" rowspan="1" colspan="1">0.62</td></tr><tr><td align="left" rowspan="1" colspan="1">EuroSCORE 2</td><td align="center" rowspan="1" colspan="1">2.51&#x000b1;1.34</td><td align="center" rowspan="1" colspan="1">2.29&#x000b1;1.36</td><td align="center" rowspan="1" colspan="1">0.42</td></tr><tr><td align="left" rowspan="1" colspan="1">Preoperative serum creatinine (mg/dl)</td><td align="center" rowspan="1" colspan="1">1.02&#x000b1;0.3</td><td align="center" rowspan="1" colspan="1">1.12&#x000b1;0.4</td><td align="center" rowspan="1" colspan="1">0.19</td></tr><tr><td align="left" rowspan="1" colspan="1">Creatinine 48 hour postoperative (mg/dl)</td><td align="center" rowspan="1" colspan="1">0.93&#x000b1;0.28</td><td align="center" rowspan="1" colspan="1">0.90&#x000b1;0.12</td><td align="center" rowspan="1" colspan="1">0.48</td></tr><tr><td align="left" rowspan="1" colspan="1">Preoperative ejection fraction (%)</td><td align="center" rowspan="1" colspan="1">56.0&#x000b1;5.2</td><td align="center" rowspan="1" colspan="1">55.6&#x000b1;4.9</td><td align="center" rowspan="1" colspan="1">0.63</td></tr><tr><td align="left" rowspan="1" colspan="1">Aortic cross clamp time (min)</td><td align="center" rowspan="1" colspan="1">58.9&#x000b1;10.3</td><td align="center" rowspan="1" colspan="1">66.3&#x000b1;11.2</td><td align="center" rowspan="1" colspan="1">0.23</td></tr><tr><td align="left" rowspan="1" colspan="1">Cardiopulmonary bypass time (min)</td><td align="center" rowspan="1" colspan="1">73.8&#x000b1;16.5</td><td align="center" rowspan="1" colspan="1">76.4&#x000b1;16.9</td><td align="center" rowspan="1" colspan="1">0.43</td></tr><tr><td align="left" rowspan="1" colspan="1">Mechanical ventilation time (hrs.)</td><td align="center" rowspan="1" colspan="1">6.83&#x000b1;2.33</td><td align="center" rowspan="1" colspan="1">6.34&#x000b1;2.10</td><td align="center" rowspan="1" colspan="1">0.63</td></tr><tr><td align="left" rowspan="1" colspan="1">ICU stay (days)</td><td align="center" rowspan="1" colspan="1">6.39&#x000b1;2.17</td><td align="center" rowspan="1" colspan="1">6.76&#x000b1;2.64</td><td align="center" rowspan="1" colspan="1">0.74</td></tr><tr><td align="left" rowspan="1" colspan="1">Hospital stay (days)</td><td align="center" rowspan="1" colspan="1">8.63&#x000b1;3.20</td><td align="center" rowspan="1" colspan="1">8.08&#x000b1;2.52</td><td align="center" rowspan="1" colspan="1">0.72</td></tr><tr><td align="left" rowspan="1" colspan="1">Maximum inotropic score</td><td align="center" rowspan="1" colspan="1">6.3&#x000b1;2.52</td><td align="center" rowspan="1" colspan="1">6.&#x000b1;2.13</td><td align="center" rowspan="1" colspan="1">0.65</td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative new onset AF</td><td align="center" rowspan="1" colspan="1">5 (8.9%)</td><td align="center" rowspan="1" colspan="1">7 (12.9%)</td><td align="center" rowspan="1" colspan="1">0.12</td></tr><tr><td align="left" rowspan="1" colspan="1">Myocardial infarction</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>AF = atrial fibrillation; ICU = intensive care unit</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Cardiac biomarkers.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">CPK-MB (U/l)</th><th align="center" rowspan="1" colspan="1">Group 1</th><th align="center" rowspan="1" colspan="1">Group 2</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;6 hours</td><td align="center" rowspan="1" colspan="1">62.9&#x000b1;27.6</td><td align="center" rowspan="1" colspan="1">69.1&#x000b1; 22.7</td><td align="center" rowspan="1" colspan="1">0.19</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;12 hours</td><td align="center" rowspan="1" colspan="1">59.6&#x000b1;27.4</td><td align="center" rowspan="1" colspan="1">61.01&#x000b1;22.6</td><td align="center" rowspan="1" colspan="1">0.24</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;1 day</td><td align="center" rowspan="1" colspan="1">52.7&#x000b1;20.3</td><td align="center" rowspan="1" colspan="1">55.3&#x000b1;21.3</td><td align="center" rowspan="1" colspan="1">0.21</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;2 day</td><td align="center" rowspan="1" colspan="1">41.6&#x000b1;19.7</td><td align="center" rowspan="1" colspan="1">46.4&#x000b1;19.1</td><td align="center" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Serum troponin I (ng/ml)</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;6 hours</td><td align="center" rowspan="1" colspan="1">10.62&#x000b1;2.89</td><td align="center" rowspan="1" colspan="1">11.08&#x000b1;2.91</td><td align="center" rowspan="1" colspan="1">0.89</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;12 hours</td><td align="center" rowspan="1" colspan="1">7.08&#x000b1;2.34</td><td align="center" rowspan="1" colspan="1">7.32&#x000b1;2.10</td><td align="center" rowspan="1" colspan="1">0.78</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;1 day</td><td align="center" rowspan="1" colspan="1">4.63&#x000b1;1.09</td><td align="center" rowspan="1" colspan="1">4.92&#x000b1;1.20</td><td align="center" rowspan="1" colspan="1">1.23</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;2 day</td><td align="center" rowspan="1" colspan="1">2.46&#x000b1;0.42</td><td align="center" rowspan="1" colspan="1">2.86&#x000b1;0.56</td><td align="center" rowspan="1" colspan="1">1.20</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Serum lactate (ng/dl)</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;6 hours</td><td align="center" rowspan="1" colspan="1">6.0&#x000b1;1.4</td><td align="center" rowspan="1" colspan="1">6.3&#x000b1;1.2</td><td align="center" rowspan="1" colspan="1">0.06</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;12 hours</td><td align="center" rowspan="1" colspan="1">4.08&#x000b1;1.1</td><td align="center" rowspan="1" colspan="1">4.4&#x000b1;1.2</td><td align="center" rowspan="1" colspan="1">0.46</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;1 day</td><td align="center" rowspan="1" colspan="1">2.3&#x000b1;1.3</td><td align="center" rowspan="1" colspan="1">2.6&#x000b1; 1.5</td><td align="center" rowspan="1" colspan="1">0.77</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;2 day</td><td align="center" rowspan="1" colspan="1">1.7&#x000b1;0.3</td><td align="center" rowspan="1" colspan="1">1.9&#x000b1;0.5</td><td align="center" rowspan="1" colspan="1">0.62</td></tr></tbody></table></table-wrap><table-wrap id="t4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Cardiac output parameters.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Cardiac output parameters</th><th align="center" rowspan="1" colspan="1">Group 1</th><th align="center" rowspan="1" colspan="1">Group 2</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Cardiac index (l/min/m<sup>2</sup>)</td><td align="center" colspan="3" rowspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;12 hours</td><td align="center" rowspan="1" colspan="1">3.33&#x000b1;0.6</td><td align="center" rowspan="1" colspan="1">3.38&#x000b1;0.5</td><td align="center" rowspan="1" colspan="1">0.66</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;24 hours</td><td align="center" rowspan="1" colspan="1">3.32&#x000b1;0.7</td><td align="center" rowspan="1" colspan="1">3.27&#x000b1;0.6</td><td align="center" rowspan="1" colspan="1">0.67</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;36 hours</td><td align="center" rowspan="1" colspan="1">3.44&#x000b1;0.5</td><td align="center" rowspan="1" colspan="1">3.45&#x000b1;0.5</td><td align="center" rowspan="1" colspan="1">0.87</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Left ventricle stroke work index
(ml/m<sup>2</sup>)</bold></td><td align="center" colspan="3" rowspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;12 hours</td><td align="center" rowspan="1" colspan="1">56.5&#x000b1;8.5</td><td align="center" rowspan="1" colspan="1">54.5&#x000b1;8.6</td><td align="center" rowspan="1" colspan="1">0.23</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;24 hours</td><td align="center" rowspan="1" colspan="1">53.1&#x000b1;9.1</td><td align="center" rowspan="1" colspan="1">54.4&#x000b1;9.8</td><td align="center" rowspan="1" colspan="1">0.15</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;36 hours</td><td align="center" rowspan="1" colspan="1">56.1&#x000b1;8.7</td><td align="center" rowspan="1" colspan="1">55.1&#x000b1;10.0</td><td align="center" rowspan="1" colspan="1">0.98</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Right ventricle stroke work index
(ml/m<sup>2</sup>)</bold></td><td align="center" colspan="3" rowspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;12 hours</td><td align="center" rowspan="1" colspan="1">4.2&#x000b1;1.14</td><td align="center" rowspan="1" colspan="1">4.2&#x000b1;1.2</td><td align="center" rowspan="1" colspan="1">0.95</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;24 hours</td><td align="center" rowspan="1" colspan="1">4.3&#x000b1;1.1</td><td align="center" rowspan="1" colspan="1">4.2&#x000b1;1.0</td><td align="center" rowspan="1" colspan="1">0.47</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;36 hours</td><td align="center" rowspan="1" colspan="1">4.34&#x000b1;0.9</td><td align="center" rowspan="1" colspan="1">4.2&#x000b1;0.8</td><td align="center" rowspan="1" colspan="1">0.52</td></tr></tbody></table></table-wrap></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Lignocaine is classified as a sodium channel blocker and is class 1B antiarrhythmic.
Intraoperative and postoperative arrhythmias were relatively less frequent but not
statistical significant in single-dose cardioplegia group as compared with ST 1 B
group. Blood cardioplegia is associated with significant reduction in postoperative
arrhythmias as compared to crystalloid cardioplegia. Both our cardioplegias were
blood-based. Leicher et al.<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup> in
their study concluded that K<sup>+</sup> induced increase coronary vascular
resistance can be revented by lignocaine<sup>[<xref rid="r6" ref-type="bibr">6</xref>-<xref rid="r8" ref-type="bibr">8</xref>]</sup>.</p><p>There was no statistically significant difference for cross clamp and CPB times
between the two groups. The shorter cross clamp times did not translate into any
benefit in mortality or morbidity in terms of ventilation time, ICU stay or
inotropic score.</p><p>Serum CPK-MB peaked in first 6 hours and started decreasing after 12 hours. CPK-MB
levels of more than five times the basal value was taken as marker for perioperative
myocardial infarction. It reached baseline level on 3<sup>rd</sup> to 4<sup>th</sup>
day postoperatively. CPK-MB level was slightly higher in ST 1 B group than
single-dose blood cardioplegia group. However, there was no statistically
significant difference between the two groups. Long-term follow-up studies by Costa
et al.<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup> and Klatte et
al.<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup> have shown that
patients with peak CK-MB release of more than 5 times the upper limit of normal
continue to have a relatively high risk of mortality even after the first 30
postoperative days. However, in this study it never increased to 5 times above basal
values<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>.</p><p>The serum troponin I release in the post-operative period was maximum at 6 hours with
gradual decline at 48 hours. The enzyme release was less in single-dose blood
cardioplegia group as compared to the ST 1 B group, but it was not found to be
statistically significant. In this study, shorter cross clamp time and less release
of myocardial injury markers found in single-dose blood cardioplegia group, but this
did not translate into any clinical benefit, as there was no difference in both
groups in terms of inotropic score, ventilation time or ICU stay. This can be
attributed to exclusion of high-risk patients<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>.</p><p>Single-dose blood cardioplegia group had slightly lower levels of serum lactate as
compared to ST 1 B group at all point of time. However, there was no statistically
significant difference in serum lactate level in both groups. In this study, high
levels were found 6 hours after surgery, which were normalized after 12 hours.
Immediate higher levels were not related with any form of postoperative morbidity
and mortality in our patients. There was no statistically significant difference
between the two groups, providing evidence of equal efficacy of single-dose blood
cardioplegia and multiple doses of ST 1 B. Lactate levels in this study corresponds
to the accepted in value most of the other studies<sup>[<xref rid="r12" ref-type="bibr">12</xref>,<xref rid="r13" ref-type="bibr">13</xref>]</sup>.</p><p>Heart receives insult not only from inflammation caused by CPB, but also by repeated
ischemia and reperfusions. The most potent anti-inflammatory substances are
steroids. However, many studies demonstrated the role of steroids in reducing CPB
related injury. Studies by Sellevold et al.<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup> suggested that inclusion of steroid improved the recovery
of physiological indices, reduced CK leakage, increased myocardial ATP, reduced
myocardial edema and prevented ischemia induced myocardial damage<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>. In the present study, we did not
find any beneficial effect of steroid inclusion in our cardioplegia.</p><p>Myocardial edema also impairs myocardial function. Hyperosmotic mannitol scavenges
free radicals and reduces myocardial cell swelling<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup>. Magovern et al.<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup> demonstrated in rabbit heart preparations the
superiority of mannitol (as compared to the glucose containing hyperosmolar solution
and isosmolar solution) in improving in postischaemic ventricular function and
reducing myocardial edema formation. There was no any statistical significant
difference in ventricular function, inotropic score, and arrhythmias between the two
groups. Inclusion of mannitol in this cardioplegia did not translate any statistical
significant difference in selected patients with good ventricular functions.
However, these constituents may provide their beneficial effects in patients with
decompensated hearts.</p><p>We did not find any statistical significant difference in coronary sinus blood sample
parameters.</p><p>Inclusion of additives like lignocaine, mannitol, and steroid did not offer any
obvious benefit in prevention of various postoperative arrhythmias in study groups.
They would have given extra benefits in patients with poor ejection fraction and
high-risk patients. There was no any statistically significant difference between
the two groups. Therefore, it was presumed that single-dose blood cardioplegia being
a blood-based cardioplegia would be superior to other long-acting crystalloid
cardioplegias in terms of postoperative arrhythmias. However, this can only be
proved in a randomized control study comparing single-dose blood cardioplegia with
other long-acting crystalloid cardioplegia.</p><p>Markers of myocardial function like cardiac index, left and right ventricle stroke
work index at 12, 24 and 36 hours and 2D echocardiography was performed on
5<sup>th</sup> postoperative day were comparable between both groups. The
postoperative indices of left and right ventricle functions in this study were
comparable to the other studies done for patients with preserved myocardial
function<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup>.</p><sec><title>Limitations</title><p>This study was a prospective randomized controlled study between single-dose
lignocaine based-blood cardioplegia and multidose short-acting blood-based
cardioplegia. Single-dose blood cardioplegia has proved to be equally safe and
effective as short-acting ST 1 B cardioplegia in low-risk patients, single valve
pathology and surgery requiring shorter cross clamp time.</p><list list-type="order"><list-item><p>This study included a relatively small sample size.</p></list-item><list-item><p>This study did not compare single-dose blood cardioplegia with other
long-acting crystalloid cardioplegias. Further studies are required to
compare the single-dose blood cardioplegia with other long-acting
crystalloid cardioplegia in patients with complex cardiac procedures,
which might require longer aortic cross clamp time.</p></list-item><list-item><p>Given the non-inferiority of single-dose blood cardioplegia now, further
studies need to be undertaken to compare single-dose blood cardioplegia
with St Thomas I blood-based cardioplegia in high-risk and compromised
patients. Until then, St Thomas I blood-based cardioplegia will continue
to be gold standard cardioplegia.</p></list-item></list></sec></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>This study proves the safety and efficacy of long-acting lignocaine-based single-dose
blood cardioplegia compared to the standard short acting multidose blood
cardioplegia in patients requiring the single valve replacement. Further studies
need to be undertaken to establish this non-inferiority in situations of complex
cardiac procedures especially in compromised patients.</p><table-wrap id="t6" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="10%" span="1"/><col width="90%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">JR</td><td align="left" rowspan="1" colspan="1">Conception and design study; realization of operations;
<break/>analysis and/or data interpretation; statistical analysis;
<break/>manuscript redaction or critical review of its content;
<break/>final manuscript approval</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AM</td><td align="left" rowspan="1" colspan="1">Conception and design study; realization of operations;
<break/>analysis and/or data interpretation; statistical analysis;
<break/>manuscript redaction or critical review of its content;
<break/>final manuscript approval</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">VW</td><td align="left" rowspan="1" colspan="1">Conception and design study; realization of operations;
<break/>analysis and/or data interpretation; statistical analysis;
<break/>manuscript redaction or critical review of its content;
<break/>final manuscript approval</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PS</td><td align="left" rowspan="1" colspan="1">Conception and design study; realization of operations;
<break/>analysis and/or data interpretation; statistical analysis;
<break/>manuscript redaction or critical review of its content;
<break/>final manuscript approval</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PG</td><td align="left" rowspan="1" colspan="1">Conception and design study; realization of operations;
<break/>analysis and/or data interpretation; statistical analysis;
<break/>manuscript redaction or critical review of its content;
<break/>final manuscript approval</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MT</td><td align="left" rowspan="1" colspan="1">Conception and design study; realization of operations;
<break/>analysis and/or data interpretation; statistical analysis;
<break/>manuscript redaction or critical review of its content;
<break/>final manuscript approval</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HP</td><td align="left" rowspan="1" colspan="1">Conception and design study; realization of operations;
<break/>analysis and/or data interpretation; statistical analysis;
<break/>manuscript redaction or critical review of its content;
<break/>final manuscript approval</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn><fn fn-type="other"><p>This study was carried out at the U.N. Mehta Institute of Cardiology and Research
Center (Affiliated to B.J. Medical College), Civil Hospital Campus, Asarwa,
Ahmedabad, India.</p></fn><fn fn-type="supported-by"><p>No financial support.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Brien</surname><given-names>JD</given-names></name><name><surname>Howlett</surname><given-names>SE</given-names></name><name><surname>Burton</surname><given-names>HJ</given-names></name><name><surname>O'Blenes</surname><given-names>SB</given-names></name><name><surname>Litz</surname><given-names>DS</given-names></name><name><surname>Friesen</surname><given-names>CL</given-names></name></person-group><article-title>Pediatric cardioplegia strategy results in enhanced calcium
metabolism and lower serum troponin T</article-title><source>Ann Thorac Surg</source><year>2009</year><volume>87</volume><issue>5</issue><fpage>1517</fpage><lpage>1523</lpage><pub-id pub-id-type="pmid">19379896</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliveira</surname><given-names>MAB</given-names></name><name><surname>Godoy</surname><given-names>MF</given-names></name><name><surname>Braile</surname><given-names>DM</given-names></name><name><surname>Lima-Oliveira</surname><given-names>APM</given-names></name></person-group><article-title>Polarizing cardioplegic solution: state of the
art</article-title><source>Braz J Cardiovasc Surg</source><year>2005</year><volume>20</volume><issue>1</issue><fpage>69</fpage><lpage>74</lpage></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sobrosa</surname><given-names>CG</given-names></name><name><surname>Jansson</surname><given-names>E</given-names></name><name><surname>Kaijser</surname><given-names>L</given-names></name><name><surname>Bomfim</surname><given-names>V</given-names></name></person-group><article-title>Myocardial metabolism after hypothermic retrograde continuous
blood cardioplegia with anterograde warm cardioplegic
induction</article-title><source>Braz J Cardiovasc Surg</source><year>2005</year><volume>20</volume><issue>4</issue><fpage>416</fpage><lpage>422</lpage></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacob</surname><given-names>S</given-names></name><name><surname>Kallikourdis</surname><given-names>A</given-names></name><name><surname>Sellke</surname><given-names>F</given-names></name><name><surname>Dunning</surname><given-names>J</given-names></name></person-group><article-title>Is blood cardioplegia superior to crystalloid
cardioplegia</article-title><source>Interact Cardiovasc Thorac Surg</source><year>2008</year><volume>7</volume><issue>3</issue><fpage>491</fpage><lpage>498</lpage><pub-id pub-id-type="pmid">18339688</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leicher</surname><given-names>FG</given-names></name><name><surname>Magrassi</surname><given-names>P</given-names></name><name><surname>LaRaia</surname><given-names>PJ</given-names></name><name><surname>Derkac</surname><given-names>WM</given-names></name><name><surname>Buckley</surname><given-names>MJ</given-names></name><name><surname>Austen</surname><given-names>WG</given-names></name></person-group><article-title>Blood cardioplegia delivery: deleterious effects of potassium
versus lidocaine</article-title><source>Ann Surg</source><year>1983</year><volume>198</volume><issue>3</issue><fpage>266</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">6615050</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sellevold</surname><given-names>OF</given-names></name><name><surname>Jynge</surname><given-names>P</given-names></name></person-group><article-title>An experimental evaluation of glucocorticoid supplementation to
cardioplegic solutions in clinical use</article-title><source>Thorac Cardiovasc Surg</source><year>1985</year><volume>33</volume><issue>2</issue><fpage>65</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">2409626</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dias</surname><given-names>RR</given-names></name><name><surname>Dalva</surname><given-names>M</given-names></name><name><surname>Santos</surname><given-names>B</given-names></name><name><surname>Kwasnicka</surname><given-names>KL</given-names></name><name><surname>Sarraff</surname><given-names>AP</given-names></name><name><surname>Dias</surname><given-names>AR</given-names></name><etal/></person-group><article-title>Influence of lidocaine on myocardial protection with blood
cardioplegia</article-title><source>Braz J Cardiovasc Surg</source><year>2002</year><volume>17</volume><issue>3</issue><fpage>215</fpage><lpage>220</lpage></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dussin</surname><given-names>LH</given-names></name><name><surname>Moura</surname><given-names>L</given-names></name><name><surname>Gib</surname><given-names>MC</given-names></name><name><surname>Saadi</surname><given-names>EK</given-names></name><name><surname>Barbosa</surname><given-names>GV</given-names></name><name><surname>Wender</surname><given-names>OCB</given-names></name></person-group><article-title>Ultrastructural study of the myocardium using cardioplegic
crystalloid solution with and without procaine in patients undergoing aortic
valve replacement</article-title><source>Braz J Cardiovasc Surg</source><year>2008</year><volume>23</volume><issue>3</issue><fpage>389</fpage><lpage>395</lpage></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>MA</given-names></name><name><surname>Carere</surname><given-names>RG</given-names></name><name><surname>Lichtenstein</surname><given-names>SV</given-names></name><name><surname>Foley</surname><given-names>DP</given-names></name><name><surname>Valk</surname><given-names>V</given-names></name><name><surname>Lindenboom</surname><given-names>W</given-names></name><etal/></person-group><article-title>Incidence, predictors, and significance of abnormal cardiac
enzyme rise in patients treated with bypass surgery in the Arterial
Revascularization Therapies Study (ARTS)</article-title><source>Circulation</source><year>2001</year><volume>104</volume><issue>22</issue><fpage>2689</fpage><lpage>2693</lpage><pub-id pub-id-type="pmid">11723020</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klatte</surname><given-names>K</given-names></name><name><surname>Chaitman</surname><given-names>BR</given-names></name><name><surname>Theroux</surname><given-names>P</given-names></name><name><surname>Gavard</surname><given-names>JA</given-names></name><name><surname>Stocke</surname><given-names>K</given-names></name><name><surname>Boyce</surname><given-names>S</given-names></name><etal/></person-group><article-title>Increased mortality after coronary artery bypass graft surgery is
associated with increased levels of postoperative creatine kinase-myocardial
band isoenzyme release: results from the GUARDIAN trial</article-title><source>J Am Coll Cardiol</source><year>2001</year><volume>38</volume><issue>4</issue><fpage>1070</fpage><lpage>1077</lpage><pub-id pub-id-type="pmid">11583884</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>PS</given-names></name><name><surname>Pereira</surname><given-names>SN</given-names></name><name><surname>Moraes</surname><given-names>LB</given-names></name><name><surname>Marques</surname><given-names>RS</given-names></name><name><surname>Alvarez</surname><given-names>MAP</given-names></name><name><surname>Daudt</surname><given-names>CAS</given-names></name><etal/></person-group><article-title>Oxygenated cardioplegia in myocardial protection during cardiac
surgery: a clinical and enzymatic study</article-title><source>Braz J Cardiovasc Surg</source><year>1988</year><volume>3</volume><issue>3</issue><fpage>210</fpage><lpage>215</lpage></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobson</surname><given-names>GP</given-names></name><name><surname>Faggian</surname><given-names>G</given-names></name><name><surname>Onorati</surname><given-names>F</given-names></name><name><surname>Vinten-Johansen</surname><given-names>J</given-names></name></person-group><article-title>Hyperkalemic cardioplegia for adult and pediatric surgery: end of
an era?</article-title><source>Front Physiol</source><year>2013</year><volume>4</volume><fpage>228</fpage><lpage>228</lpage><pub-id pub-id-type="pmid">24009586</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Blenes</surname><given-names>SB</given-names></name><name><surname>Friesen</surname><given-names>CH</given-names></name><name><surname>Ali</surname><given-names>A</given-names></name><name><surname>Howlett</surname><given-names>S</given-names></name></person-group><article-title>Protecting the aged heart during cardiac surgery: the potential
benefits of del Nido cardioplegia</article-title><source>J Thorac Cardiovasc Surg</source><year>2011</year><volume>141</volume><issue>3</issue><fpage>762</fpage><lpage>770</lpage><pub-id pub-id-type="pmid">20656301</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joudi</surname><given-names>M</given-names></name><name><surname>Fathi</surname><given-names>M</given-names></name><name><surname>Soltani</surname><given-names>G</given-names></name><name><surname>Izanloo</surname><given-names>A</given-names></name></person-group><article-title>Factors affecting on serum lactate after cardiac
surgery</article-title><source>Anesth Pain Med</source><year>2014</year><volume>4</volume><issue>4</issue><elocation-id>e18514</elocation-id><pub-id pub-id-type="pmid">25632379</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shinde</surname><given-names>SB</given-names></name><name><surname>Golam</surname><given-names>KK</given-names></name><name><surname>Kumar</surname><given-names>P</given-names></name><name><surname>Patil</surname><given-names>ND</given-names></name></person-group><article-title>Blood lactate levels during cardiopulmonary bypass for valvular
heart surgery</article-title><source>Ann Card Anaesth</source><year>2005</year><volume>8</volume><issue>1</issue><fpage>39</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">17823485</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magovern</surname><given-names>GJ Jr</given-names></name><name><surname>Bolling</surname><given-names>SF</given-names></name><name><surname>Casale</surname><given-names>AS</given-names></name><name><surname>Bulkley</surname><given-names>BH</given-names></name><name><surname>Gardner</surname><given-names>TJ</given-names></name></person-group><article-title>The mechanism of mannitol in reducing ischemic injury:
hyperosmolarity or hydroxyl scavenger?</article-title><source>Circulation</source><year>1984</year><month>9</month><volume>70</volume><issue>3</issue><issue-part>Pt 2</issue-part><fpage>I91</fpage><lpage>I95</lpage><pub-id pub-id-type="pmid">6086178</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mullen</surname><given-names>JC</given-names></name><name><surname>Fremes</surname><given-names>SE</given-names></name><name><surname>Weisel</surname><given-names>RD</given-names></name><name><surname>Christakis</surname><given-names>GT</given-names></name><name><surname>Ivanov</surname><given-names>J</given-names></name><name><surname>Madonik</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Right ventricular function: a comparison between blood and
crystalloid cardioplegia</article-title><source>Ann Thorac Surg</source><year>1987</year><volume>43</volume><issue>1</issue><fpage>17</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">3541813</pub-id></element-citation></ref></ref-list></back></article>